Index

abstract see reporting
accounting for clustering see analysis and sample size calculations
adaptive design 62
adherence see also compliance piloting 64
adjusted chi-squared test 105–106, 118–119, 122, 131
allocation 6, 8, 14, 24, 33, 35–40, 62–63, 74
  balance 77–78, 82, 100, 255
  post-allocation recruitment 202
allocation concealment 35, 199, 245
allocation ratio 62, 85, 222, 237–239
allocation sequence 244–245
analysis see also Bayesian analyses,
accounting for baseline characteristics 104, 107, 109
ancillary see reporting and CONSORT checklist
available case see analysis, complete case
binary outcomes see binary outcomes calculating ICCs from 175, 185, 189–191
cluster size 7
cluster-level see cluster-level analysis 7 complete case 259
confounders see analysis, covariates
continuous outcomes see continuous outcomes
count outcomes see count outcomes covariates 107, 219, 220, 249
ignoring clustering 7, 101–102, 200
imputation in 129, 257
individual-level 107, 109, 131
individually randomised trials 1
intention-to-treat 129, 257
interim 232–233
intra-cluster correlation 104
minimisation factors in 104, 248
missing values 129
analysis see also Bayesian analyses (cont’d)
  multiple comparisons 125, 126
  per protocol 233, 259
  pilot studies 62–63, 72
  small numbers of clusters 107
  stratification factors in 104, 248
  subgroup see also CONSORT checklist 258
  time-to-event outcomes see time-to-event outcomes
  trial aims 121
  two-stage 106
  weighted 102, 105, 107, 124, 126, 128, 151, 259
  analysis of covariance, cluster-level 107–108, 125
  analysis planning 131–132
  attrition see loss to follow up
  average cluster size see cluster size
  baseline, change from 119, 166–167
  baseline assessment 5, 35, 74, 86–87, 120
  number of participants 140
  timing of 246
  baseline covariates
    adjustment for 104, 107–109, 113, 115, 120
  baseline data see also reporting and CONSORT checklist
    balancing trial arms 76–77, 79, 163, 165
    associated with outcome 163, 167
    calculating ICC from 183
    comparison between arms 120, 219
    ICC estimate from 183
    imbalance 246, 255
    imbalance between arms 108
    minimisation, use in 113
  Bayesian analysis see also cost effectiveness analyses
    binary outcomes 122
    continuous outcomes 116
  Bayesian hierarchical models 17
  beta-binomial model 122, 190
  beta distribution for ICCs 179
  between-cluster coefficient of variation 10, 145, 151, 156
  between-cluster variability 7, 102, 112, 234
  accounting for in analysis 128
  between-cluster variance as a measure of 154
  coefficient of variation of outcome as a measure of 138, 156–157, 173
  factors affecting 9
  ICC as a measure of 7, 137, 156–157
  measuring 9–10, 104, 138, 173
  between-cluster variance 112
  cluster-specific model (binary outcomes) 190
  cluster-specific model (continuous outcomes) 112
  continuous outcomes 156
  intervention to reduce 160
  logistic scale 190
  matched designs 162
  measuring 154–155
  prior distribution 116
  relationship with coefficient of variation of binary outcomes 157
  relationship with ICC (binary outcomes) 157–160
  relationship with ICC (continuous outcomes) 174
  sample size calculations 154–155
  stratified designs 161
  bias 10, 13
    allocation concealment 35
    allocation sequence 244–245
    analysis 115–116
    blinding see blinding
    blocking 83
    cluster allocation 33
    cluster drop out 150, 200
    cost effectiveness analyses 212
    drop out 41
    identification and recruitment see also recruitment bias
      recruitment bias 4, 18, 200, 246
    indicator of quality 218–219
    informed consent, relationship with 33
    intention to treat 129–130
    interim analyses 244
    internal validity 13–14, 35–40
    intra-cluster correlation coefficients 186
    process evaluation 213
    publication 228
    randomisation 76
    recruitment see recruitment bias reporting 229, 260
INDEX  269

reporting associated with 220
response 219
sample size and analysis 220
selection 14
stratification 165
systematic reviews 199, 201, 207
tossing a coin 75

binary outcomes
analysis on logistic scale 119, 120
analysis see adjusted chi-squared test, Bayesian analyses, beta-binomial model, cluster-level t-test, generalised estimating equations, mixed effects models, Bayesian analyses, beta-binomial model, Wilcoxon
calculating ICC 185
cluster-specific model 117–118
comparison of analysis methods 122
ICC 173, 174, 185, 190
influence of prevalence on ICC 178–179
popularity 109
population-averaged model 117–118
sample size calculation 142, 150, 161
summary at cluster level 102–104

blinding 8, 14, 199–200
allocation see allocation concealment 14
and quality 199
delivery of intervention 199
outcome assessment 153, 199–200
participants 199–200
purpose 14
recruitment of participants 4–7, 24, 35–40
reporting see reporting
block size 83
blocking see also reporting and CONSORT checklist 79, 82–83, 166
matching 84
stratification 78
bootstrap
cost effectiveness analysis 210–212
variance of intra-cluster correlation 192–193

CASP see quality of trials
chi-square test see also adjusted chi-squared test 7
clinical diversity 201
clinical guidelines 107–108, 208
clinically important difference 138, 140–141, 228
cluster consent see consent
cluster guardians 30–32
cluster randomisation see randomisation
cluster randomisation rationale see also reporting and CONSORT checklist 10–13, 219, 234
cluster randomised trial, rationale for see cluster randomisation rationale
cluster representation mechanism 32
cluster size
analysed 7
average 139
average in sample size calculation 150, 151
balancing, use in 76
cluster level t-test 105
coefficient of variation of 151
CONSORT flow chart, reporting in 249
definition 7
definition for sample size 139
ignoring variability in sample size calculation 152
incident cases 153–154
individual-level analyses 109
mean see cluster size, average
natural 7, 78, 139, 178
pseudo-cluster randomisation 95
relationship with ICC 178
reporting in sample size calculation 243
required if fixed number of clusters 143
small 153
standard deviation of 151
stratification factor, use as 163
variability and analysis 102, 114, 116
variability and sample size 140, 150–151, 154
variation when recruiting from UK general practices 152, 198
weighting by 102, 105, 107, 126, 128
cluster summary statistics 17
cluster-level analysis 17, 130–131
number of clusters 107
cluster-level data 99–100
cluster-level t-test 102–103, 105
comparison with other methods 122, 129
degrees of freedom 149
cluster-level t-test (cont’d)
   matched design 124, 163
   weighted 107
clusters, number required 142, 150
   minimum number required 148
   restricted number 146–148
cluster-specific effects 109–110
cluster-specific model
   Bayesian approach 116, 122
   binary outcomes 117–120
   continuous outcomes 112–114
   number of clusters 118
cluster-specific odds ratio 118
Cochrane collaboration 197
Cochrane database 234
Cochrane handbook 197, 198, 199, 200, 207, 215
coefficient of variation of cluster size 140, 151–154, 243
coefficient of variation of outcome see also reporting 10, 137, 138, 145, 156–160
   relationship with between-cluster variance (binary outcomes) 159
   relationship with ICC (binary outcomes) 158
cohort design 107, 108
   versus cross-sectional 85–87, 166, 202
community intervention trials 1, 45, 124, 145
completely randomised design 75–76
   analysis 104, 105
   disadvantages 76
complex intervention 18, 196
   definition 46
   graphical method for describing 241–242
   lack of effect 45
   minimally important difference 140
   phases in development 44
   process evaluation 212–213
complex intervention development
   causal modelling 54
   exploratory trial phase 55–57
   fractional factorial design 56
   intervention modelling experiments 55, 56
   modelling 53–56
   pilot studies 61
   pre-clinical phase 50–53
   qualitative studies 69
   theoretical framework 52
compliance see also adherence
   between-cluster variability in 131
   improving 25, 202
confidence interval
   accounting for clustering 102–104
   for ICC 176
   pilot studies, estimates from 70–72
   width 7, 103
consent see also reporting 4–7, 18, 24
   clusters 30–32, 33
   components 25
   data collection 5–6, 25, 63
   educational programmes 33
   information to clusters 33
   information to participants 8–9, 41
   participation 25, 28
   process evaluation of procedures 213
   randomisation 24, 25, 30, 32
   recommendations for researchers 35
   timing of 6
   validity of trial 16, 260
CONSORT 17, 199, 218–219
   checklist 221–226
   cluster randomised trials 227, 232
   extensions 227
CONSORT checklist
   adherence 223
   allocation concealment 224
   analysis 225
   ancillary analyses 226
   background 222
   baseline data 225
   bias 226
   blinding 222, 224, 226
   blocking 224
   cluster size 224
   confidence intervals 225
   data collection 222
   effect size 225
   eligibility 222–223
   external validity 226
   funding 226
   generalisability 226
   harms 226
   ICC 225
   intervention 223, 224
intervention implementation 224
number of clusters 224
objectives 222
outcomes 223
protocol 222–226
randomisation 224
rationale for cluster randomisation 222
sample size 224
subgroup analysis 225, 226
title 222
CONSORT flow chart 101, 249–252, 257
contamination
crossover trials 94
health professional level 11–12
individual-level 12
individual-cluster interventions 25–26
pseudo cluster randomised trials 95
continuous outcomes
analysis see cluster level t-test,
Bayesian analyses, generalised estimating equations, mixed effects models, Wilcoxon
cluster specific model 110–112
comparison of analysis methods 116
ICC 185
population-averaged model 110–111
sample size calculation 142, 150, 161
cost data
correlation with outcomes 208–207
ICC for 208–209
skewed 210, 212
cost effectiveness analyses 208–212
Bayesian approach 210
bivariate multilevel model 209
bivariate regression 209
few clusters 211, 212
generalised estimating equations 211
least squares regression 209
missing data 212
multilevel model 209
robust variance methods 211
seemingly unrelated regression 211
skewed cost data 212
two-stage bootstrap 210
variable cluster size 212
cost of intervention, unequal allocation 166, 238
count outcomes 122–124
covariate adjustment
use in calculating ICCs 189
cluster-level 107–108
for matched designs 124
individual-level 109
individual-level (binary outcomes) 117–119
individual-level (continuous outcomes) 110–113, 115–116
individual-level (count outcomes) 123
use in sample size calculation 167
covariates in analysis planning 131
Cox’s proportional hazards 124
cross-sectional design 85–87
analysis 87, 107
CONSORT flow chart 250
crossover trial 94
meta-analysis 202
sample size 166–167
crossover design 92
analysis 92, 128
extension to CONSORT 227
sample size 169
DAMOCLES 214
data collection see also consent, reporting
and CONSORT checklist 99–101
baseline 35
burden of 41
cohort design 86
data monitoring committee 214
from records 27
internal pilot 62
opt out 29, 30
piloting 66
process evaluation 212
repeated cross-sectional design 86–87, 107, 202
routine data 99
data monitoring committee 214
charter 214
interim analyses 244
INDEX

data monitoring committee (cont’d)
  internal pilots 63
  protocol changes 239
delayed intervention 96
design effect
  accounting for stratification by cluster size 165
  calculating confidence intervals, use in 258
  for rates 145
  limited numbers of clusters 148
  meta-analysis, use in 203–206
  using the intra-cluster correlation coefficient 142–143
  variable cluster size 150–151
drop out see also loss to follow-up
  clusters 33, 41, 150
  handling in analysis 129
  participants 41
  piloting 70
  small numbers of clusters 149
effect size see also CONSORT checklist
  bias in 129
  cluster-specific model (binary outcomes) 118–119
  cluster-specific model (continuous outcomes) 112
  in pilot studies 72
  meta-analysis 203
  population-averaged model (binary outcomes) 118–119
  population-averaged model (continuous outcomes) 111
  small 228
  variance of 151
effective sample size 203–205
  variation in cluster size 204
effectiveness
  avoiding overestimation 129
  in pragmatic trials 14
  lack of 45–46
  optimising 66
  publication bias 228
  secular trend in 83
efficacy 2
  drug 228
  explanatory trials 3, 15
eligibility see also CONSORT checklist
  clusters 239
  participants 239
  protocol changes 239
  reporting 231
Equator network 230, 263
equivalence trials 95
  CONSORT extension 227
ethical issues 14–16
  consent see consent
  definition of intervention components 57
  duty of care to control patients 34–35
  harms see also CONSORT checklist 24, 31, 33, 214, 226, 228
  protecting privacy 33
  rationale for cluster randomisation 234
  with individual randomisation 10
ethics and internal validity 15, 219
ethics committee 24, 214, 239
exploratory trial 3, 31
exploratory trial 50, 55–57, 68
external validity 13–14, 219
  consent 41
  definition 13
  elements of 14–15
  lack of 14
  selection of clusters 22–23
  selection of participants 23–24
factorial design
  analysis 126
  definition 89
  interaction, antagonistic 91, 92
  interaction, synergistic 91
  fractional 56, 90
  full 89–90
feasibility study 60–61
  compared with pilot studies 61
  criteria for feasibility 70
  definition 62
  intervention 66
  objectives 69–70
  randomisation in 62, 63
  rationale 63–64
  reporting 71
flow chart see also CONSORT flow chart
  causal modelling, use in 54
  identification and recruitment bias, to identify 40
funding see also CONSORT checklist 141
process evaluations 213
funding applications 46, 239

generalisability see reporting and CONSORT checklist 13
generalised estimating equations
binary outcomes 119–120
calculating ICCs 185, 191
continuous outcomes 113–114
cost effectiveness analyses 211
count outcomes 122–123
negative ICC 132, 191
number of clusters 114, 120, 122, 132
good clinical practice 214
graphical display of intervention 241–242
group allocation see allocation
group randomisation see randomisation

harms see ethical issues
heterogeneity
clinical diversity 201
I² statistic 201
meta-analysis 203
methodological diversity 201
Q-test 201
repeated cross sectional design 202
variability in cluster size 202
hierarchical design 112
history of cluster randomised trials 16–17, 201

ICC see also ICC, calculating 7, 9–10
combining estimates 182–185
costs 208
definition 173–175
design effect 142
estimating from matched design 84
interpretation in CRT 175
Kappa interpretation 174–175
lists 138, 176–178
logistic scale 190–191
natural cluster size 178
negative 116, 120, 174, 186, 188, 189, 191, 259
pair-wise correlation interpretation 174, 185, 187–188

patterns in 178–179
planning analysis 131
primary care 142, 178
process measures 178
proportion of variance interpretation 185, 173–174
relationship with prevalence of outcome 178–179
reporting 243
sample size, use in 179–185
secondary care 178
sources of estimates 172, 175–179
ICC, calculating see also ICC 17, 185–191
analysis of variance method 119, 186–187
ccluster-specific model 119
surveys 175
GEE model 191
logistic-normal 190
mixed effects models 189–191
Pearson product-moment correlation coefficient 187–189
pilot studies 64, 68, 71
pilot study 180–182
precision 172, 176, 180, 181, 192
random effects 189–190
trial reports 180, 175–176
variance 192
variance using Bootstrap approach 193
variance using Fisher’s formula 192
variance using Swiger’s formula 181, 192
identification and recruitment bias see recruitment bias
incremental net benefits 207, 210
individual-level analyses see analysis
individual-level covariates see covariate adjustment
infectious diseases 8, 16, 145
informed consent see consent
intention-to-treat see analysis
interactions see factorial designs
interim analyses 232
internal validity 219, 260, 261, 13–15
definition 13
intervention
acceptability 68, 70
acute conditions 6
antagonistic interventions 91
intervention (cont’d)
- as delivered 8, 15
- awareness campaigns 33
- blinding 14, 199
- blinding of non-pharmocological 224
- clinical diversity 201
- cluster-cluster 25, 28, 37, 57, 202
- complex 8–9, 18, 44, 46–49
- complex, graphical description 241–242
- compliance see also compliance 25
- content 66, 197, 201
- control arm 34, 260
- cost 12, 64, 147, 166
- CRT 1, 8
- defining 44, 57
- delivery 66, 67, 94, 197, 201, 212, 223, 247
- educational 8, 33
- effectiveness 83
- external validity 15, 23–24
- external-cluster 27–28, 57, 202
- fidelity 58, 214
- fidelity, enhancing 213
- fidelity, monitoring 213
- form 66, 197, 201
- implementation 12–13, 225
- individual-cluster 25, 26, 57, 95, 202
- intensity 66, 197, 201
- lack of effectiveness 45–46
- medical intervention definition 2
- modelling see complex intervention development
- multifaceted 29–30, 57, 202
- multi-layered 57
- opt-out 24, 25, 29, 63
- piloting see complex intervention development
- pragmatic 34
- professional-cluster 27, 57, 151, 202
- reporting blinding 247–248
- intra-cluster correlation coefficient see ICC

Jadad score 219

Kappa statistic see ICC
Kruskal-Wallis test 126

limitations see reporting
link function 119

logistic regression 109, 122, 132, 258
logistic-normal regression model 119, 122
loss to follow up see also reporting 219
- clusters 33, 41, 84, 150, 153, 200
- individuals 41, 87, 140
- piloting 70
- sample size 139, 143, 146
- low-income countries 1, 33, 34, 124, 138, 145, 165

Mann-Witney U test 126
Mantel-Haenzel methods in meta-analyses 206
matched design 18, 74, 84–85, 220, 221, 237
- analysis 124–125
- number of clusters 125
- sample size 160–163
- sample size for means 161
- sample size for proportions 161–162
- matching correlation 162
- matching factors 163–164
- maximum likelihood 115, 151
- cost effectiveness 209, 211
- restricted 115
- maximum likelihood estimator, number of clusters 115
Medline 232
MeSH terms 232, 234
meta-analysis 197, 203, 205
- analysis, use in 125
- fixed effects 203
- heterogeneity 201, 203
- I² statistic 201
- individual patient data 206
- matched designs 206–207
- random effects 203
- reporting 207
- trial quality 198, 200
- trials using stratification or matching 206
meta-regression 203
minimisation 76, 79–82
- analysis 104–107, 108, 113, 248
- blocking 83
- disadvantages 80
- number of clusters 80
- programs 244
- random element 80
reporting 244
sample size 166
missing data 129–131, 257
cost-effectiveness 212
imputation 129, 257
reporting 257, 259
mixed effects models 112
  binary outcomes 120–122
calculating ICCs 185, 189–191
  continuous outcomes 117, 114–116
count data 122–124
instability 127
matched designs 125
  number of clusters 116, 121, 131
Poisson 122–124
  sample size 151
estimating ICCs from 189–191
monitoring
data monitoring committee 214, 239, 244
  intervention fidelity 58, 213–214
multilevel models 17
  multi-arm trials 2, 74, 88–92
    analysis 125–126
mixed effects models 125
  sample size 167–168
multilevel modelling 112, 115, 127, 128
  cost effectiveness analyses 211, 212, 208–210
natural cluster size see cluster size
non-inferiority trials 95
  reporting 228, 237
non-parametric test 105, 107, 124, 126
  number of clusters 107
non-pharmacological interventions 46, 53, 222–226, 227, 228, 239
normalisation process theory 56
  number of clusters 221, 250, 252
  balance 149, 255
drop outs 150
  reporting see also CONSORT checklist 243
number of clusters, small 149
  reasons 146–148
odds ratio 160
  adjusted chi-squared 119
  cluster-specific 118
GEE 119, 132
  population-averaged 118
stratified design 161
ordinal data 132
over-dispersion 124
  paired t-test 124, 163
parallel design 75, 237
  multi-arm design 88
two-arm 75, 237
permutation test 116, 122, 125, 106–107
PICO 14, 197
pilot study
  aims 61, 63, 68, 69, 70, 71, 72
  definition 60–61
  design 69
external 62, 63
  ICC estimation 68
  internal 62
intervention 66–68
  outcomes 68–69
protocol 71
randomisation 63–66
  recruitment 63–65
reporting 72
  sample size of 70
placebo 1, 2, 14, 25, 245
Poisson regression 109, 122
  GEE 122
odds ratio 118
power 16, 18, 139, 228, 260
crossover designs 128
factorial designs 91, 93
  matching 84, 160, 163
  multi-arm 167
pilot study 70, 71, 72
  small number of clusters 137, 148, 149
stratification 161, 206
  variability in cluster size 78, 151
pragmatic trials 2–3, 14, 222–226
  blinding 199, 248
external validity 250
  interventions 34
pragmatic trials (cont’d)
  reporting 227
  pre-specifying 229
process evaluation 196, 215, 260, 212–213
  intervention fidelity 212–213
  qualitative methods 212
prognostic factors 74, 76, 165, 206
  balancing factors 82
  matching 84
  minimisation 79–80
proportions, difference between 102, 104, 117, 142, 160
protocol 32, 35, 41, 239
  analysis plan 259
  changes to 114, 239, 243
  pilot studies 62, 63, 71
  publication 213, 218, 227
pseudo cluster randomisation 95
  analysis 128–129
public health interventions 25, 34, 141
  cost effectiveness analyses 208
  publication bias 228–229
QALY 207
Q-test 201
qualitative methods
  intervention development 55, 57, 69
  intervention understanding 55
  process evaluation 212
quality criteria 221
quality of trials 215, 198–200, 218–219
  assessment of 196, 197, 200, 207, 218–221
CASP checklist 219
  checklists 219
  criteria 199, 200, 221
  external validity 13, 261
  reporting see also CONSORT
    checklist 17, 218, 222–226
randomisation 1, 4–7, 16, 18
  balance 76
  balance, cluster size 78
  balance, individual factors 76
  blocking 74, 78, 79, 82–83, 166
  completely randomised 75–76
  consent to see consent to randomisation
    individual level and cluster level 92
  matching see also matched designs 84
  piloting 62–66
  pseudo cluster randomisation 95
  reasons for cluster randomisation see
    cluster randomisation rationale
  reporting see reporting and CONSORT
    checklist
  restricted see also minimisation,
    stratification, matched designs 76, 244
  sequence generation 199, 244
  small number of clusters 149–150
  stepped wedge 95
  stratification see also stratified
    designs 78–79
  subversion of allocation 245
  unit of 4, 201, 207, 237, 250
  randomised permuted blocks 83
recruitment 4–7, 18, 200
  challenges 24
  internal validity see also recruitment
    bias 22, 33, 35–40
  piloting 63–66
  and retention 41
  recruitment bias 13, 14, 65, 95, 200, 229
  reporting see also CONSORT
    checklist 207, 229, 260, 252
  recruitment rates 40, 63, 64, 70, 212
  reporting 225, 229
  trial 218, 226, 232, 262, 227
regression analysis 109
  number of analysed units 116
  see also Poisson regression, logistic
  regression
  relative risk 160, 258
repeated cross-sectional design 94,
repeated measures 220
  reporting 196, 197
    abstract 230–232
    abstract checklist 230
    adherence 250
    allocation 245–246
    ancillary analyses 258
    background 234–237
    baseline data 255–257
    blinding 247, 260
    blocking 244
    coefficient of variation of outcome 257
    complex intervention 234
consent 231
generalisability 261
guidelines 17
ICC 132, 175, 257, 259
intervention 46, 201, 212, 223, 235, 240–241
intervention implementation 58
limitations 260
loss to follow up 150, 200, 257
methods of analysis 248
minimisation 81
objectives 237
odds ratio 258
outcomes 229, 241
outcomes, selective 199
pilot study title 72
quality 219
rationale for cluster randomisation 234
recruitment bias 246
results 257–259
sample size 143, 243
selective reporting 229
title 232, 234
trial design 235, 237, 260, 237–239
reporting of systematic reviews 207
restricted designs see randomisation,
restricted
restricted maximum likelihood 115
restricted randomisation see randomisation
retention see lost to follow-up
risk assessment 214
risk difference see also proportions 258
robust standard errors 17, 211
robust variance estimator 113, 211
routine data 13, 37, 60, 68, 76, 99–100
sample size 220, 223
ICC 8, 137, 138
ICC constant across intervention
groups 142, 156–160
interim calculations 172, 183
number of clusters, effect of ICC 148
pilot study 70–72
rates 137, 145
sample size calculations
accounting for clustering 7, 10, 17, 100, 220, 262
between-cluster variance
methods 154–155
block randomisation 166
coefficient of variation method 156
cost effectiveness analyses 211
crossover trials 169
factorial design 90–93, 168
fixed number of clusters 143–144
incident cases 152–154
individually randomised trial 141–142
matched design 161
means 155, 156
minimisation 166
number of clusters 142–143
proportions 155, 157
proportions, comparison of
methods 157–160
rates 145
repeated cross-sectional design 167
reporting 243, 257
small number of clusters 149
stratified designs 161–166
three or more arms 167
unequal numbers in intervention
arms 166
variability in cluster size 150–152
sample size, choosing ICC 179–185
baseline data 183
combining ICC estimates 182–185
health services research 173
interim data 183
patterns in ICCs 182, 184
pilot study estimate 180, 184
previous study 180
sensitivity analysis 185
single estimate 184
cost effectiveness analyses 211
selection bias see also bias and recruitment
bias 14
selection of individuals see recruitment bias
selective reporting
interim analysis 244
outcomes 199, 229–230, 243, 257
sequence generation see allocation
sequence 199
setting 13–15, 22–23, 55, 239, 261
setting, effect on ICC 178
significance (statistical), in sample size
139
significance level, falsely significant 7, 220
small numbers of clusters
analysis see GEE and mixed effects models
estimating ICC 181–182
rationale 146–148
split-plot 92
standard deviation, confidence interval
for 71
Standard Protocol Items for Randomised Trials (SPIRIT) initiative 230
stepped wedge design 95, 128, 129
stopping rules 62
stratification 128, 220, 221
number of clusters 78, 83, 108
stratification factors
choosing 163
cluster size as 163–164
stratified design 18, 75, 76, 78–80, 244
analysis 104, 105, 108, 248
blocking 83
minimisation used with 81
power 165–166
sample size 160–162
stratified random sampling 78, 79
subgroup analyses see also CONSORT checklist 258
summary statistics at cluster-level 17
superiority trials 95
survival outcomes see time-to-event outcomes
Swiger’s variance formula for ICCs 181
systematic reviews 14, 18, 196–197
assessment of trial quality 207, 198–200
inclusion criteria 197
methodological diversity 201
units of randomisation 198, 201, 202, 205, 207
systematic reviews 197–207
clinical diversity 201
intervention development 51
variability in cluster size 202
weighting of studies 200, 203
three or more arms see multi-arm trials
time-to-event outcomes 109, 124
treatment groups 232
trial quality see quality of trials
trial status 232
t-test 7, 102, 103, 104, 105, 107, 122, 126, 129, 149
weighting 107
UK MRC framework for complex interventions 18
units of observation 4–5
units of randomisation 4, 241, 250
unpublished trials 228, 230
variability between clusters see between-cluster variability
variance between clusters see between-cluster variance
variance inflation factor 142
variance of ICCs see ICC
variance within clusters see also within-cluster variance
variances, modelling and estimation
mixed effects models 116, 121
generalised estimating equation 113
in sample size 160
weighting in analysis
cluster size, use in 102, 105, 126, 128, 151
inverse variance 105, 128, 151
t-test 105, 107
Wilcoxon
matched pairs test 124
rank sum test 122
within-cluster homogeneity 7, 9, 173
within-cluster variance see also between-cluster variance 112, 155, 156, 157, 174, 186